<DOC>
	<DOCNO>NCT00445510</DOCNO>
	<brief_summary>This single centre , randomise , double-blind , placebo-controlled , 2-period crossover study investigate effect treatment repeat inhaled dos GSK256066 bronchial hyper-reactivity adenosine monophosphate .</brief_summary>
	<brief_title>This Study Will Examine Effects GSK256066 Protect Mild Steroid-naive Asthmatics Against Antigen Challenge</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Inclusion : ( All must Apply ) Males female age 18 55 year inclusive . Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta agonist therapy inhalation . Prebronchodilator FEV1 &gt; 75 % predict screening . Documented sensitivity AMP provocative concentration AMP result 20 % fall FEV1 ( PC20 AMP ) &lt; 80 mg/ml screen visit . Demonstrate stable bronchoconstriction response inhale AMP runin visit . 'Stable bronchoconstriction ' term define population asthmatic repeatable reproducible response challenge agent induces bronchoconstriction . The runin PC20 need within 1.25DD screen PC20 . Nonsmoking status verify urinary cotinine level 300 ng/mL cotinine screen visit . This include exsmokers give smoke &gt; 6 month le 5 packyear smoke history . Able willing give write informed consent take part study . Available complete study measurement . Exclusion : Pregnant nursing female . Past present disease , judge investigator , may affect outcome study . Subject known history hypertension hypertensive screening . Respiratory tract infection and/or exacerbation asthma within 4 week prior first dose study medication . History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizure . Unable abstain prescription medication , short act inhaled betaagonists paracetamol treatment minor ailment eg headache 48h first dose followup visit . The subject participate clinical trial previous 3 month . History blood donation ( 450 mL ) within 2 month start clinical study . The subject regularly drink 28 unit alcohol week male , 21 unit per week female . The subject test positive hepatitis C antibody hepatitis B surface antigen HIV antibody . The subject positive drug abuse test . Subjects weigh less 50kg exclude participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>GSK256066 ,</keyword>
	<keyword>allergen ,</keyword>
	<keyword>challenge ,</keyword>
	<keyword>repeat dose ,</keyword>
	<keyword>AMP ,</keyword>
	<keyword>mild asthmatic</keyword>
</DOC>